Improved gene transfer and normalized enzyme levels in primitive hematopoietic progenitors from patients with mucopolysaccharidosis type I using a bioreactor

Journal of Gene Medicine

Volumn 6, Issue 12, 2004, Pages 1293-1303

  Pan, Dao ^a,c   Stroncek, David F ^b   Whitley, Chester B ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Hollow fiber bioreactor; Long term in vitro hematopoiesis; Mucopolysaccharidosis; Retroviral; Stem cell

Indexed keywords

LEVO IDURONIDASE; RETROVIRUS VECTOR;

ARTICLE; BIOREACTOR; CD34 SELECTION; CELL CULTURE; CELL LINEAGE; COLONY FORMING CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME MEMBRANE BIOREACTOR; GENE EXPRESSION; GENE FREQUENCY; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HOLLOW FIBER; HUMAN; HUMAN CELL; HURLER SYNDROME; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STEM CELL GENE THERAPY; ULTRAFILTRATION; VIRAL GENE DELIVERY SYSTEM;

ANTIGENS, CD34; BIOREACTORS; CELL CULTURE TECHNIQUES; FILTRATION; GENE EXPRESSION PROFILING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; MUCOPOLYSACCHARIDOSIS I; RETROVIRIDAE; STEM CELLS; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 14244268255     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.621     Document Type: Article

References (55)

1. Crystal RG. Transfer of genes to human: early lessons and obstacles to success. Science 1995; 270: 404-410.
2. Richter J, Karlsson S. Clinical gene therapy in hematology: past and future. Int J Hematol 2001; 73: 162-169.
3. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048-3057.
4. Chabannon C, Olivero S, Blaise D, et al. Ex vivo expansion of human hematopoietic progenitors and cells to support high-dose chemoradiation therapy: five years of clinical experience. Cytokines, Cell Mol Ther 2000; 6: 97-108.
5. Engel BC, Kohn DB. Stem cell directed gene therapy. Front Biosci 1999; 4: e26-33.
6. Murray L, Luens K, Tushinski R, et al. Optimization of retroviral gene transduction of mobilized primitive hematopoietic progenitors by using thrombopoietin, Flt3, and Kit ligands and RetroNectin culture. Hum Gene Ther 1999; 10: 1743-1752.
7. Piacibello W, Sanavio F, Severino A, et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood 1999; 93: 3736-3749.
8. + progenitors using clinically feasible methods. Mol Ther 2000; 1: 285-293.
9. Orlic D, Girard LJ, Anderson SM, et al. Identification of human and mouse hematopoietic stem cell populations expressing high levels of mRNA encoding retrovirus receptors. Blood 1998; 91: 3247-3254.
10. MacNeill EC, Hanenburg H, Pollok KE, et al. Simultaneous infection with retroviruses pseudotyped with different envelope proteins bypasses viral receptor interference associated with colocalization of gp70 and target cells on fibronectin CH-296. J Virol 1999; 73: 3960-3967.
11. Schilz AJ, Schiedlmeier B, Kuhlcke K, et al. MDR1 gene expression in NOD/SCID repopulating cells after retroviral gene transfer under clinically relevant conditions. Mol Ther 2000; 2: 609-618.
12. + cells that mediate long-term engraftment of NOD/ SCID mice by HIV vectors. Science 1999; 283: 682-686.
13. Guenechea G, Gan OI, Inamitsu T, et al. Transduction of human CD34 + CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. Mol Ther 2000; 1 566-573.
14. Bahnson AB, Dunigan JT, Baysal BE, et al. Centrifugal enhancement of retroviral mediated gene transfer. J Virol Methods 1995; 54: 131-143.
15. Bunnell BA, Muul LM, Donahue RE, et al. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1995; 92 7739-7743.
16. Hanenberg H, Xiao XL, Dilloo D, et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996; 2: 876-882.
17. Moore KA, Deisseroth, AB, Reading, CL, et al. Stromal support enhances cell-free retroviral vector transduction of human bone marrow long-term culture-initiating cells. Blood 1992; 79: 1393-1399.
18. Bennaceur-Griscelli A, Pondarre C, Schiavon V, et al. Stromal cells retard the differentiation of CD34(+)CD38(low/neg) human primitive progenitors exposed to cytokines independent of their mitotic history. Blood 2001; 97: 435-441.
19. Abonour R, Williams DA, Einhorn L, et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000; 6: 652-658.
20. Hacein-Bey S, Gross F, Nusbaum P, et al. Optimization of retroviral gene transfer protocol to maintain the lymphoid potential of progenitor cells. Hum Gene Ther 2001; 12: 291-301.
21. Hennemann B, Chuo JY, Schley PD, et al. High-efficiency retroviral transduction of mammalian cells on positively charged surfaces. Hum Gene Ther 2000; 11: 43-51.
22. + cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 1998; 9: 2629-2640.
23. + cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87: 1687-1691.
24. Inoue Y, Lopez LB, Kawamoto S, et al. Production of recombinant human monoclonal antibody using ras-amplified BHK-21 cells in a protein-free medium. Biosci Biotechnol Biochem 1996; 60: 811-817.
25. Knight P. Hollow fiber bioreactors for mammalian cell culture. Bio/Technology 1989; 7: 459.
26. Packard BS. Mitogenic stimulation of human tumor-infiltrating lymphocytes by secreted factor(s) from human tumor cell lines. Proc Natl Acad Sci U S A 1990; 87: 4058-4062.
27. Bano M, Salomon DS, Kidwell WR. Purification of a mammary-derived growth factor from human milk and human mammary tumor. J Biol Sci 1985; 260: 5745-5752.
28. Liu JJ, Chen BS, Tsai TF, et al. Long term and large-scale cultivation of human hepatoma Hep G2 cells in hollow fiber bioreactor. Cytotechnology 1991; 5: 129-139.
29. Pan D, Shankar R, Stroncek DF, et al. Combined ultrafiltration-transduction in a hollow-fiber bioreactor facilitates retrovirus-mediated gene transfer into peripheral blood lymphocytes from patients with mucopolysaccharidosis type II. Hum Gene Ther 1999; 10: 2799-2810.
30. Hopwood JJ, Morris CP. The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment. Mol Biol Med 1990; 7: 381-404.
31. Whitley CB. Bone marrow transplantation for Hurler syndrome: assessment of metabolic correction. Birth Defects 1987; 22: 7-24.
32. Krall WJ, Challita PM, Perlmutter LS, et al. Cells expressing human glucocerebrosidase from a retroviral vector repopulate macrophages and central nervous system microglia after murine bone marrow transplantation. Blood 1994; 83: 2737-2748.
33. Pan D, Aronovich E, McIvor RS, et al. Retroviral vector design studies toward hematopoietic stem cell gene therapy for mucopolysaccharidosis type I. Gene Ther 2000; 7: 1875-1883.
34. Whitley CB, Gorlin RJ, Krivit W. A nonpathologic allele (IW) for low alpha-L-iduronidase enzyme activity vis-a-vis prenatal diagnosis of Hurler syndrome. Am J Med Genet 1987; 28: 233-243.
35. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
36. + cells in peripheral and cord blood by flow cytometry. Exp Hematol 1994; 22: 1003-1010.
37. Sutherland HJ, Eaves CJ, Lansdorp PM, et al. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 1991; 78: 666-672.
38. Verfaillie CK, Blakolmer K, McGlave P. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. J Exp Med 1990; 172: 509-520.
39. Halene S, Kohn DB. Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest. Hum Gene Ther 2000; 11: 1259-1267.
40. van der Loo JCM, Liu BL, Goldman AI, et al. Optimization of gene transfer into primitive human hematopoietic cells of granulocyte-colony stimulating factor-mobilized peripheral blood using low-dose cytokines and comparison of a gibbon ape leukemia virus versus an RD114-pseudotyped retroviral vector. Hum Gene Ther 2002; 13 1317-1330.
41. + progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction. Blood 1997; 89: 446-456.
42. + cells is superior to G-CSF or G-CSF+Flt3-L-mobilized cells in nonhuman primates. Blood 2003; 101: 2199-2205.
43. Orlic D, Girard LJ, Jordan CT, et al. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc Natl Acad Sci U S A 1996; 93: 11 097-11 102.
44. Kiem HP, Heyward S, Winkler A, et al. Gene transfer into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. Blood 1997; 90: 4638-4645.
45. Case SS, Price MA, Jordan CT, et al. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A 1999; 96: 2988-2993.
46. Uchida N, Sutton RE, Friera AM, et al. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci U S A 1998; 95: 11 939-11 944.
47. Kotani H, Newton PB III, Zhang S, et al. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994; 5: 19-28.
48. Conneally E, Eaves CJ, Humphries RK. Efficient retroviral-mediated gene transfer to human cord blood stem cells with in vivo repopulating potential. Blood 1998; 91: 3487-3493.
49. van Hennik PB, Verstegen MM, Bierhuizen MF, et al. Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice. Blood 1998; 92: 4013-4022.
50. Marandin A, Dubart A, Pflumio F, et al. Retrovirus-mediated gene transfer into human CD34 + 38low primitive cells capable of reconstituting long-term cultures in vitro and nonobese diabetic-severe combined immunodeficiency mice in vivo. Hum Gene Ther 1998; 9: 1497-1511.
51. Fairbairn LJ, Lashford LS, Spooncer E, et al. Long-term in vitro correction of alpha-L-iduronidase deficiency (Hurler syndrome) in human bone marrow. Proc Natl Acad Sci U S A 1996; 93: 2025-2030.
52. Huang MM, Wong A, Yu X, et al. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts. Gene Ther 1997; 4: 1150-1159.
53. Pan D, Jonsson JJ, Braun SE, et al. "Supercharged Cells" for delivery of recombinant human iduronate-2-sulfatase. Mol Genet Metabol 2000; 70: 170-178.
54. Demirer T, Buckner CD, Bensinger WI. Optimization of peripheral blood stem cell mobilization. Stem Cells 1996; 14: 106-116.
55. Korbling M, Fliedner TM. The evolution of clinical peripheral blood stem cell transplantation. Bone Marrow Transplantation 1996; 17: 675-678.